



IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Sector \$3  
Box Sec 4  
PATENT

In re application of:

Applicants Robert L. Gendron and : Paper No:  
Helene Paradis

Serial No. 09/836,410 : Group Art Unit: 1645

Filed: April 17, 2001 : Examiner:

For: INHIBITION OF BONE TUMOR FORMATION USING ANTISENSE cDNA THERAPY

RESPONSE

THE ASSISTANT COMMISSIONER FOR PATENTS  
Washington, D.C. 20231

Dear Sir:

In response to the Office Action, dated June 4, 2001, please consider the following remarks.

Attached hereto, as requested by the Examiner, is a computer-readable disk of the sequence listings for the above patent application (prepared using PatentIn 3.1), as required by 37 C.F.R. 1.821(e). Additionally, corresponding hard-copy listings of these sequences are also enclosed.

I hereby state that the information recorded on said disk in computer-readable form is identical to the written sequence listing of the pending application. I further state that the submission made herein, filed in accordance with 37 CFR 1.821(g), does not include any new matter.

Respectfully submitted,

ROBERT L. GENDRON  
HELENE PARADIS


*Karlyn A. Schnapp*  
Karlyn A. Schnapp  
Registration No. 45,558  
Telephone (513) 651-6865  
FROST BROWN TODD LLC  
2200 PNC Center  
201 East Fifth Street  
Cincinnati, Ohio 45202-4182

Dated: June 15, 2001

**CERTIFICATE OF MAILING**

I hereby certify that a copy of this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to The Assistant Commissioner of Patents, Washington, D.C. 20231 this 15<sup>th</sup> day of January, 2001.





## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
 UNITED STATES PATENT AND TRADEMARK OFFICE  
 WASHINGTON, D.C. 20231  
 www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/836,410	04/17/2001	Robert L. Gendron	

CONFIRMATION NO. 7267

## FORMALITIES LETTER



\*OC00000006140765\*

Frost Brown Todd LLC  
 2200 PNC Center  
 201 East Fifth Street  
 Cincinnati, OH 45202

Date Mailed: 06/04/2001

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
 CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
 DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

Refund Ref: 08/02/2001 TLU11 0000107847

CHECK Refund Total: \$65.00

06/22/2001 TLU11-  
 00000003 09/36410 65.00 OP  
 08/02/2001 TLU11-  
 00000003 09/36410 65.00 OP  
 01 FC:205  
 01 FC:205  
 01 FC:205  
 01 FC:205

*A copy of this notice **MUST** be returned with the reply.*

*qjgm*  
Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE